Zentalis Pharmaceuticals, Inc.
About Zentalis Pharmaceuticals, Inc.
Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $0
- Net income
- -$137.1M
- Total assets
- $289.0M
- Market cap
- $260.5M
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $152.8M
- Operating income
- -$152.8M
- Income tax
- $442.0K
- Net income
- -$137.1M
- EPS (basic)
- $-1.91
- EPS (diluted)
- $-1.91
Balance sheet
- Total assets
- $289.0M
- Current assets
- $253.2M
- Total liabilities
- $72.8M
- Current liabilities
- $36.6M
- Shareholders’ equity
- $216.2M
Cash flow
- Operating cash flow
- -$125.2M
- Investing cash flow
- $131.6M
- Financing cash flow
- -$4.3M
- Net cash flow
- $2.1M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $260.5M
- EPS (diluted)
- $-1.91
- Shares outstanding
- 72.8M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Apr 3, 2020
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $137.1M in FY2025.
- Trading 46% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Zentalis Pharmaceuticals, Inc..
Write a review
News about Zentalis Pharmaceuticals, Inc.
News & sentiment via Polygon.io
